论文部分内容阅读
目的评价应用细胞因子诱导的杀伤细胞(CIK)过继免疫治疗晚期胃癌的有效性。方法用淋巴细胞分离液分离出单个核细胞,将诱导后的CIK细胞回输给晚期胃癌患者。采用流式细胞术分析CIK培养过程中与55例晚期胃癌患者治疗前后外周血中的T细胞亚群(CD3+,CD4+,CD8+)、CIK细胞(CD3+CD56+)及NK细胞(CD3-CD56+)的变化,并应用生化比色法与免疫分析技术检测患者治疗前后血清恶性肿瘤相关物质(TSGF)、胃癌相关抗原(MG7-Ag)、糖类抗原19-9(CA19-9)和癌胚抗原(CEA)含量。结果CIK细胞对K562细胞的细胞毒活性在14~21d时达峰值。CD3+CD56+细胞由起初的(0.7±0.4)%上升到14d的(31.6±5.5)%与21d的(35.8±9.7)%。经CIK细胞治疗后患者的肿瘤标志物水平下降,而NK与T细胞亚群水平明显升高,且CIK升高尤为显著,同时提高了患者的生活质量。总缓解率61.8%。结论用CIK细胞回输治疗晚期胃癌患者可提高患者的细胞免疫功能,并改善其临床体征,无明显毒副作用。
Objective To evaluate the efficacy of adoptive immunization of cytokine-induced killer cells (CIK) in the treatment of advanced gastric cancer. Methods Mononuclear cells were isolated from lymphocytes and the induced CIK cells were transfused to patients with advanced gastric cancer. Flow cytometry was used to analyze the changes of T cell subsets (CD3 +, CD4 +, CD8 +), CIK cells (CD3 + CD56 +) and NK cells (CD3-CD56 +) in peripheral blood of 55 patients with advanced gastric cancer before and after CIK culture using flow cytometry (TSGF), gastric cancer associated antigen (MG7-Ag), carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (ESCC) were detected by biochemical colorimetry and immunoassay before and after treatment CEA) content. Results The cytotoxic activity of CIK cells on K562 cells reached its peak at 14-21 days. CD3 + CD56 + cells increased from the initial (0.7 ± 0.4)% to (31.6 ± 5.5)% of 14d and (35.8 ± 9.7)% of 21d. After CIK cell therapy, the level of tumor markers decreased, while the level of NK and T cell subsets increased significantly, and CIK increased particularly significantly, while improving the quality of life of patients. The overall response rate was 61.8%. Conclusions CIK cell transplantation in the treatment of advanced gastric cancer patients can improve cellular immune function, and improve their clinical signs, no obvious side effects.